Texas Neurofibromatosis Foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2015
NCT02332902
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now